Ratio Therapeutics

The Partner of Choice for Next-Generation Radiopharmaceutical Development

Boston, United States · Founded 2021 · $70.0M raised

Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$70.0M
Last Round
$50.0M Series BJan 2024
Rounds
2

About

Ratio Therapeutics is a Boston-based clinical-stage biopharmaceutical company developing next-generation targeted radiopharmaceuticals for the treatment of cancer. Founded in 2021 by John Babich, Ph.D. and Jack Hoppin, Ph.D., Ratio employs proprietary platforms including Trillium™—a tunable structural motif that enables compounds to reversibly bind albumin, modulating pharmacokinetics to improve tumor delivery while reducing off-target exposure. The company has raised over $90 million in total financing since its 2022 public launch, and operates a 19,000 sq ft headquarters and R&D facility in Boston's Design Center.

Summary

Ratio Therapeutics is a Biotech company based in Boston, United States, founded in 2021. It has raised $70.0M in total across 2 rounds, most recently a $50.0M Series B round in Jan 2024.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BJan 2024
$50.0M

Sign up to see all 2 rounds

Series A through Series B — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Ratio Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/ratio-therapeutics"><img src="https://indexed.vc/api/badge/company/ratio-therapeutics" alt="Ratio Therapeutics on Indexed.vc" width="260" height="76" /></a>